Skip to main content
SpringerLink
Log in
Book cover

Medical Retina pp 129–141Cite as

Photodynamic Therapy: Current Guidelines for the Management of Neovascular Age-Related Macular Degeneration

  • Chapter

  • 911 Accesses

Part of the book series: Essentials in Ophthalmology ((ESSENTIALS))

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Arnold JJ, Verteporfin in Photodynamic Therapy Study Group (2001) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization — Verteporfin in Photodynamic Therapy Report 2. Am J Ophthalmol 131:541–560

    Google Scholar 

  2. Arnold JJ, Verteporfin Roundtable 2000 and 2001 Participants, TAP Study Group Principal Investigators, VIP Study Group Principal Investigators (2002) Guidelines for using Verteporfin (Visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina 22:6–18

    Google Scholar 

  3. Azab M, Benchaboune M, Blinder KJ, et al., TAP and VIP Study Group (2004) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of two-year results in three randomized clinical trials TAP and VIP Report 4. Retina 24:1–12

    PubMed  Google Scholar 

  4. Barbazetto I, Burdan A, Bressler NM, et al. (2003) Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment — TAP and VIP report No. 2. Arch Ophthalmol 121:1253–1268

    PubMed  CAS  Google Scholar 

  5. Blinder KJ, Blumenkranz MS, Bressler NM, et al. (2003) Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial — VIP report no. 3. Ophthalmology 110:667–673

    PubMed  Google Scholar 

  6. Blinder KJ, Bradley S, Bressler NM, et al. (2003) Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol 136:407–418

    PubMed  CAS  Google Scholar 

  7. Blumenkranz MS, Bressler NM, Bressler SB, et al. (2002) Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials — TAP Report no. 5. Arch Ophthalmol 12010:1307–1314

    Google Scholar 

  8. Borodoker N, Spaide RF, Maranan L, et al. (2002) Verteporfin infusion-associated pain. Am J Ophthalmol 133:211–214

    Article  PubMed  CAS  Google Scholar 

  9. Bressler NM, TAP Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with Verteporfin: two-year results of 2 randomized clinical trials — TAP Report 2. Arch Ophthalmol 119:198–207

    PubMed  CAS  Google Scholar 

  10. Bressler NM, PJ Rosenfeld, Lim JI, VIM Study Group (2003) A phase II placebo-controlled, double-masked, randomized trail — Verteporfin in minimally classic CNV due to AMD (VIM). Invest Ophthalmol Vis Sci 44:Abstract 1100

    Google Scholar 

  11. Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2002) Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition’s impact on vision outcomes — TAP Report No. 3. Arch Ophthalmol 120:1443–1454

    Google Scholar 

  12. Rosenfeld PJ, VIM Study Group (2004) Verteporfin in minimally classic CNV due to AMD (VIM) — two-year results from a phase II controlled clinical trial. Invest Ophthalmol Vis Sci 45:Abstract 2273

    Google Scholar 

  13. Rosenfeld PJ, Saperstein DA, Bressler NM, et al. (2004) Photodynamic therapy with verteporfin in ocular histoplasmosis: uncontrolled, open-label 2-year study. Ophthalmology 111:1725–1733

    Article  PubMed  Google Scholar 

  14. Rubin GS, Bressler NM (2002) Effects of Verteporfin therapy on contrast sensitivity: results from the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation — TAP Report No. 4. Retina 22:536–544

    PubMed  Google Scholar 

  15. Singerman LJ, Rosenfeld PJ, VALIO Study Group (2004) Verteporfin with altered (delayed) light in occult (VALIO) — 12-month results of a phase II controlled clinical trial. Invest Ophthalmol Vis Sci ARVO 45:Abstract 2274

    Google Scholar 

  16. Skubitz KM, Skubitz AP (1998) Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil). Anticancer Drugs 9:45–50

    PubMed  CAS  Google Scholar 

  17. Spaide RF, Maranan L (2003) Neutrophil margination as a possible mechanism for verteporfin infusion-associated pain. Am J Ophthalmol 135:549–550

    Article  PubMed  CAS  Google Scholar 

  18. Spaide RF, Donsoff I, Lam DL, et al. (2002) Treatment of polypoidal choroidal vasculopathy with photodynamic therapy. Retina 22:529–535

    PubMed  Google Scholar 

  19. Spaide RF, Freund KB, Slakter J, et al. (2002) Treatment of subfoveal choroidal neovascularization associated with multifocal choroiditis and panuveitis with photodynamic therapy. Retina 22:545–549

    PubMed  Google Scholar 

  20. Spaide RF, Martin ML, Slakter J, et al. (2002) Treatment of idiopathic subfoveal choroidal neovascular lesions using photodynamic therapy with verteporfin. Am J Ophthalmol 134:62–68

    Article  PubMed  CAS  Google Scholar 

  21. Stur M (2004) Verteporfin early retreatment (VER) — 12-month results of a phase IIIb controlled clinical trial. Invest Ophthalmol Vis Sci ARVO 45:Abstract 2275

    Google Scholar 

  22. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group (1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials — TAP report 1. Arch Ophthalmol 117:1329–1345

    Google Scholar 

  23. Verteporfin in Photodynamic Therapy Study Group (2001) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization — verteporfin in photodynamic therapy report 2. Am J Ophthalmol 131:541–560

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, St. Franziskus Hospital, Hohenzollernring 74, 48745, Münster, Germany

    Prof. Dr. Daniel Pauleikhoff & Dr. Georg Spital

Authors
  1. Prof. Dr. Daniel Pauleikhoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dr. Georg Spital
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Ophthalmology, University of Bonn, Ernst-Abbe-Straβe 2, 53127, Bonn, Germany

    Frank G. Holz MD (Professor of Ophthalmology) (Professor of Ophthalmology)

  2. Vitreous Retina-Macula Consultants of New York, 519 E 72nd St., Suite 203, New York, NY, 10021, USA

    Richard F. Spaide MD (Professor of Ophthalmology) (Professor of Ophthalmology)

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Pauleikhoff, D., Spital, G. (2005). Photodynamic Therapy: Current Guidelines for the Management of Neovascular Age-Related Macular Degeneration. In: Holz, F.G., Spaide, R.F. (eds) Medical Retina. Essentials in Ophthalmology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-27272-0_8

Download citation

  • DOI: https://doi.org/10.1007/3-540-27272-0_8

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-22596-6

  • Online ISBN: 978-3-540-27272-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation